- CSL to lay off up to 15% of workforce and spin off flu vaccine arm; shares tumble Reuters
- Markets live updates: CSL to cut more than 3,000 jobs as it ‘simplifies’ business, spins off flu arm, ASX to fall Australian Broadcasting Corporation
- Australian biopharma firm CSL posts 14% rise in annual profit MSN
- ASX extends losses; BHP rebounds, CSL tumbles The Age
- CSL to Spin Off Vaccine Unit Seqirus, Plans $487 Million Buyback Bloomberg.com
Category: 3. Business
-
CSL to lay off up to 15% of workforce and spin off flu vaccine arm; shares tumble – Reuters
-
The Commodities Feed: Oil lower on prospects of a Zelensky–Putin meeting | articles
Oil prices are marginally lower in early morning trading today, following the meeting between Presidents Trump and Zelensky. The Ukrainian leader appears to have pushed for more clarity around US security guarantees and reportedly is willing to offer a $100bn weapons deal in return for such guarantees.
There was no critical breakthrough. It appears the next step is a meeting between Zelensky and Putin, possibly within two weeks. This will be crucial, marking the first time the leaders meet since the war started. A big sticking point relates to territory. Putin wants Ukraine to concede Donetsk and Luhansk in their entirety — even parts of those regions not currently under Russian occupation. Zelensky has made it clear this isn’t something he would accept. We’ll have to wait until such a meeting to know how much flexibility there is on both the Russian and Ukrainian sides.
Betting markets aren’t overly convinced that we’ll see a ceasefire before the end of the year. Polymarkets is showing a 38% chance of a ceasefire, well below the peak of 78% seen in March. The modest price action in the oil market this morning appears to fit with this view.
The other big issue relating to Russia-Ukraine is the secondary tariffs the US placed on India for its imports of Russian oil. The deadline (27 August) to come to a deal before tariffs are introduced is nearing. To make matters worse, trade talks that were set to take place in late August have reportedly been postponed.
Finally, Ukraine said it attacked Russia’s Druzhba pipeline system, which carries crude oil to parts of central Europe. Both Hungary and Slovakia report disruptions due to the attack. Russian oil flows to both countries via the Druzhba average a little more than 200k b/d.
Continue Reading
-
Researchers investigate how citrus bioflavonoid naringin could reduce inflammation and heart risk
From endothelial repair to anti-inflammatory effects, naringin demonstrates powerful heart-protective actions before reaching clinical trials.
Systematic Review: Endothelial and Cardiovascular Effects of Naringin: A Systematic Review. Image Credit: New Africa / Shutterstock
In a recent study published in the journal Nutrients, researchers evaluated the cardiovascular and endothelial effects of naringin, a flavonoid found in citrus fruits.
Cardiovascular diseases are the leading cause of death worldwide. Among the various cardioprotective dietary bioactive compounds, flavonoids have gained significant attention for their antioxidant and anti-inflammatory capacities. Naringin is a flavanone glycoside mainly found in citrus fruits, especially in mandarin oranges and grapefruit. It has attracted considerable interest due to its multifaceted biological actions and potential cardioprotective role, though its clinical translation is limited by low oral bioavailability (<5%), prompting research into advanced delivery systems like liposomal encapsulation.
About the Study
In the present systematic review, researchers evaluated the cardiovascular and endothelial effects of naringin across cellular, animal, and human studies. First, they searched the Web of Science, PubMed, Embase, and Scopus databases to identify relevant articles published from January 2000 to June 2025. Original experimental research studies evaluating the effects of naringin on myocardial or endothelial function were included.
Reviews, editorials, abstracts, and studies without cardiovascular endpoints were excluded. Titles/abstracts were screened, followed by full text analysis based on the Population, Intervention, Comparator, and Outcomes (PICO) framework. Studies in human subjects, cell cultures, and animal models were retained. Cardiovascular or endothelial function outcomes included myocardial infarct size, blood pressure, markers of endothelial function, and cardiac remodeling, among others.
Data on study type, dose, model, treatment duration, endpoints, and mechanistic findings were extracted. A narrative synthesis approach was used due to heterogeneity in model systems, study design, and endpoints. A qualitative synthesis was performed to stratify results by primary endpoints (myocardial or endothelial function) and model type (human, cell, animal).
Naringin Molecular Structure and Citrus Food Sources. The concentration of naringin in plant sources were obtained from Alam et al.
Findings
The database search identified 2,884 unique records. The full texts of 165 records were assessed for eligibility, and 62 studies were included. These included 28 in vitro, 29 animal, and five human studies. Eight in vitro studies focused on endothelial cells and showed that naringin had protective effects on vascular endothelial cells via suppression of NF-κB signaling and adhesion molecules (e.g., VCAM-1, ICAM-1). Naringin attenuated inflammation activation and preserved normal function in cultured human endothelial cells.
Nineteen in vitro studies were on cardiovascular cell types, including five on vascular smooth muscle cells (VSMCs), and 14 on cardiac cells. Naringin was found to blunt apoptotic and hypertrophic responses in cardiomyocyte and cardiomyoblast models through modulation of PI3K/Akt and Nrf2 pathways. The anti-hypertrophic effect was related to its ability to inhibit downstream ion transporters and carbonic anhydrase II. Moreover, naringin has been shown to protect cardiomyocytes from simulated in vitro ischemia-reperfusion (I/R) by inhibiting ferroptosis and cGAS-STING pathways.
In a model of hypoxia/reoxygenation injury, naringin reduced oxidative stress, improved cell survival, and preserved mitochondrial membrane potential post-injury. Naringin has been shown to protect cardiomyocytes against doxorubicin-induced cardiotoxicity by reducing reactive oxygen species (ROS) generation and apoptosis. Further, naringin has been found to exert anti-atherogenic effects in VSMCs by curbing abnormal migration and proliferation.
Among animal studies, 15 used metabolic disorder models, with nine specifically focusing on myocardial I/R injury or hypertension. Animal models of endothelial injury and hyperlipidemia have demonstrated the anti-atherosclerotic effects of naringin. In rabbit models fed cholesterol, chronic naringin treatment reduced atherosclerotic lesion development.
Studies on hypercholesterolemic rabbits reported significant attenuation of aortic atherosclerosis with naringin treatment, associated with reduced expression of intercellular adhesion molecule 1 (ICAM-1) in the endothelium. In an atherosclerosis-prone mouse model, naringin inhibited plaque formation, protected vascular endothelium, and promoted endothelial nitric oxide synthase (eNOS) protein expression via PI3K/Akt activation.
Moreover, naringin has demonstrated anti-hypertensive effects linked to renin-angiotensin system (RAS) modulation, preventing cardiac remodeling. Studies on animal models of diet-induced metabolic syndrome have reported that naringin reduces cardiac hypertrophy and apoptosis. Beyond ischemia-reperfusion, benefits extended to diabetic cardiomyopathy, sepsis-induced myocardial dysfunction, and doxorubicin cardiotoxicity models.
In addition, naringin has consistently demonstrated cardioprotective effects in animal models of I/R injury and myocardial infarction (MI). For instance, naringin pretreatment significantly improved cardiac function and reduced myocardial damage in a rat model of I/R injury. This cardioprotection was associated with reductions in myocardial oxidative stress, inflammation, and apoptosis via PI3K/Akt and Nrf2/GPX4 pathways. In a rat model of MI, naringin pretreatment prevented myocardial necrosis and oxidative stress.
Naringin was found to improve cardiac function and histology in diabetic cardiomyopathy models and attenuate sepsis and lipopolysaccharide-induced myocardial dysfunction in other models. Further, compared to preclinical studies, few studies have examined the effects of naringin in humans. Although still limited, evidence on the cardiovascular effects of naringin in humans stems from dietary intervention studies and clinical trials.
A randomized controlled trial reported significant improvements in cardiometabolic parameters in adults who received naringin for 90 days, showing a favorable lipid-modulating effect. Notably, one trial also documented improved arterial stiffness (reduced pulse wave velocity) with naringin-rich grapefruit juice. A dietary intervention study of adults with moderate hypercholesterolemia reported that naringin intake for eight weeks did not change plasma cholesterol levels; this lack of effect might be due to insufficient dose or treatment duration, as effective preclinical doses translate to ~1 g/day in humans.
Conclusions
In sum, a substantial body of evidence positions naringin as a potent compound with cardiovascular benefits. Preclinical studies have documented its ability to protect the myocardium and improve endothelial function through multi-targeted actions on oxidative stress (Nrf2), inflammation (NF-κB), cell survival (PI3K/Akt), and RAS modulation. It can suppress oxidative stress and inflammation, preserve endothelial integrity, and activate pro-survival signaling in cells.
Despite the positive findings of naringin, further research is needed to define optimal dosing, improve bioavailability, and validate effects in large-scale human trials to cement its role in clinical practice.
Continue Reading
-
Legendary Trader Peter Brandt Just Mapped Bitcoin’s Next Peak—And It Could Hit $145K by September
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
The veteran analyst who called Bitcoin’s 2017 top is tracking a 75-week pattern that suggests crypto’s current bull run has a precise expiration date
Peter Brandt has seen enough market cycles to spot patterns that escape most traders. The legendary commodities trader, who predicted Bitcoin’s 2017 peak, just shared a striking analysis that could determine when the current crypto bull market reaches its climax.
According to Brandt’s latest research, Bitcoin bull cycles follow a remarkably consistent 75-week pattern, give or take two weeks. His analysis reveals that the 2015-2017 bull cycle lasted exactly 75 weeks, and the 2018-2021 cycle also clocked in at 75 weeks with the same margin of error.
Don’t Miss:
If this pattern holds for the current cycle that began in 2022, Brandt predicts the bull market top will arrive during the week of Sept. 22, plus or minus two weeks. This puts the potential peak window between Sept. 15 and Sept. 28.
But here’s where it gets interesting for investors: Brandt isn’t just timing the cycle—he’s pricing it too. His analysis suggests Bitcoin could reach between $125,000 and $145,000 if the historical pattern repeats.
This isn’t just chart reading—it’s pattern recognition based on multiple completed cycles that Brandt has tracked over several years.
For retail investors, this analysis offers both opportunity and warning. Bitcoin has already demonstrated its ability to follow cyclical patterns, making Brandt’s framework a valuable timing tool. However, the same pattern that could drive Bitcoin to new heights also suggests a definitive endpoint.
Trending: ‘Scrolling To UBI’ — Deloitte’s #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share.
The implications extend beyond Bitcoin itself. If the largest cryptocurrency follows this timeline, it could influence the entire crypto market’s trajectory. Altcoins typically amplify Bitcoin’s movements, meaning the September timeframe could mark peak euphoria across digital assets.
Continue Reading
-
Pakistani Youth Engagement in Stock Market
The Pakistani Stock Market is often perceived as a platform for seasoned investors, yet the real opportunity lies in empowering our youth to participate actively. With nearly 64% of Pakistan’s population under the age of 30, this demographic holds the key to expanding the investor base and fostering long-term market growth.
Young investors are naturally more adaptable to digital platforms, online trading, and innovative financial products. The PSX should take advantage of this by introducing simplified investment accounts, student-friendly trading options, and educational resources that demystify investing. Such measures would not only promote financial literacy but also help cultivate a culture of saving and investment from
an early age.
Moreover, youth-led start-ups could benefit enormously from easier access to equity financing via the PSX. Encouraging small and medium-sized enterprises (SMEs) to list on the exchange would create more diverse investment opportunities while driving innovation and job creation.
If we want a stock market that is resilient, inclusive, and forward-looking, youth engagement must be at the heart of the strategy. By combining technology, education, and opportunity, the PSX can become a true engine of national progress.
MUHAMMAD NABEEL HAIDER,
Islamabad.
Continue Reading
-
Australia's Santos flags delay in finalising ADNOC-led offer beyond deadline – Reuters
- Australia’s Santos flags delay in finalising ADNOC-led offer beyond deadline Reuters
- Disturbing history behind company in Santos takeover bid Australian Broadcasting Corporation
- Santos reveals four-week delay to ADNOC takeover deal AFR
- Santos does not expect parties to enter binding SIA by 22 August MarketScreener
- Santos Shares Fall After Another Delay in $19 Billion Takeover Bloomberg.com
Continue Reading
-
Is the AI industry in a bubble, as OpenAI CEO says?
Sam Altman, CEO of OpenAI, and Lisa Su, CEO of Advanced Micro Devices, testify during the Senate Commerce, Science and Transportation Committee hearing titled “Winning the AI Race: Strengthening U.S. Capabilities in Computing and Innovation,” in Hart building on Thursday, May 8, 2025.
Tom Williams | CQ-Roll Call, Inc. | Getty Images
There's a bubble forming in the artificial intelligence industry, according to OpenAI CEO Sam Altman.
"Are we in a phase where investors as a whole are overexcited about AI? My opinion is yes. Is AI the most important thing to happen in a very long time? My opinion is also yes," Altman said, according to a report by The Verge.
Altman's AI company is currently in talks to sell about $6 billion in stock that would value OpenAI at around $500 billion, CNBC confirmed Friday.
In another context, Altman warned that the U.S. may be underestimating the progress that China is making in AI.
Given the above premises, should investors be more cautious about OpenAI? Altman was not posed this question, but one wonders whether his opinion would also be "yes."
Outside pure-play AI companies, the money is, likewise, still flowing. Intel is receiving a $2 billion injection of cash from Japan's SoftBank.
It's a much-needed boost to the beleaguered U.S. chipmaker. Intel has fallen behind foreign rivals such as TSMC and Samsung in manufacturing semiconductors that serve as the brains for AI models.
But going by Altman's views, the investment in Intel might not be a good bet by SoftBank CEO Masayoshi Son.
Not everyone agrees with Altman, of course. Ray Wang, research director for semiconductors, supply chain and emerging technology at Futurum Group, pointed out that the AI industry is not heterogeneous. There are market leaders, and then there are companies that are still developing.
In the real world, bubbles delight because they reflect their surroundings in a play of light. But the bubble Altman described could be one doesn't show the face of its observer.
— CNBC's Dylan Butts contributed to this report
What you need to know today
Trump suggests territory 'exchanges' between Ukraine and Russia. At a White House meeting between the U.S. president, Ukrainian President Volodymyr Zelenskyy and European leaders, Trump raised that possibility as part of the peace process.
Intel is getting a $2 billion investment from SoftBank. Both companies announced the development Monday, in which SoftBank will pay $23 per share for Intel's common stock. Shares of Intel jumped more than 5% in extended trading.
The artificial intelligence market is in a bubble, says Sam Altman. Separately, the OpenAI CEO said he's "worried about China," and that the U.S. may be underestimating the latter's progress in artificial intelligence.
U.S. stocks close mostly flat on Monday. The three major indexes made moves that were less than 0.1 percentage points in either direction as investors await key U.S. retail earnings. The Stoxx Europe 600 ticked up 0.08%.
[PRO] Opportunities in one area of the European market. Investors have been pivoting away from the U.S. as multiple European indexes outperform those on Wall Street. But one pocket of Europe still remains overlooked, according to analysts.
And finally...
Brazilian President Luiz Inacio Lula da Silva and China's Great Wall Motor (GWM) CEO Mu Feng attend the opening of the GWM automobile factory on August 15, 2025, in Sao Paulo, Brazil.
China News Service | China News Service | Getty Images
China's EV industry is spending more on factories abroad than at home for the first time
For the first time since records going back to 2014, the Chinese electric car supply chain last year invested more outside the country than at home, according to a U.S.-based consulting firm Rhodium Group report published Monday.
Around 74% of announced overseas investment was in battery factories, the report said. But it noted investment in assembly plants abroad was also "growing rapidly."
— Evelyn Cheng
Continue Reading
-
Tesla starts taking orders for its new Model Y L in China from around $47,200 – Reuters
- Tesla starts taking orders for its new Model Y L in China from around $47,200 Reuters
- Tesla Model Y L started arriving at service centers across China ahead of official release CarNewsChina.com
- Tesla Stock (TSLA) Motors as Musk Launches Chinese Rescue Mission With New Model Y TipRanks
- Tesla teases a new Model Y L variant is ‘coming soon’ in a video posted to Chinese social media Business Insider
- Comprehensive Tesla Model Y L insights shared by early reviewer Teslarati
Continue Reading
-
SoftBank to invest $2 billion in Intel to become a top-10 shareholder – Reuters
- SoftBank to invest $2 billion in Intel to become a top-10 shareholder Reuters
- SoftBank Invests $2 Billion in Intel as U.S. Considers Taking 10% Stake in Chip Maker The Wall Street Journal
- SoftBank Group and Intel (INTC.O) Sign $2 Billion Investment Agreement Bitget
- Intel shares jump as Softbank to buy $2bn stake in chip giant MSN
- Softbank to invest $2 billion in Intel MarketScreener
Continue Reading
-
Australia's TPG Telecom flags cyber incident in its iiNet system – Reuters
- Australia’s TPG Telecom flags cyber incident in its iiNet system Reuters
- iiNet cyberattack exposes details of 280,000 customers 9News
- Emails, phone numbers exposed in cyberattack on second-largest internet provider Redland City Bulletin
- 280k Aussies’ data exposed in cyberattack The Advertiser
- iiNet hacked, exposing 280,000 customers The Australian
Continue Reading